Press Releases Archives | Page 45 of 117

New Peer-Reviewed Study Shows Promising Advances in Regenerative Medicine

April 7, 2023 By Cade Hildreth, Founder & President Leave a Comment

Scientists demonstrate enhanced healing capabilities of stem cells in groundbreaking research

Olathe, KS – Ronawk, a biotech and biofabrication company powered by the Bio-Block Universe™, is pleased to announce a groundbreaking new study titled “Tissue-mimetic culture enhances mesenchymal stem cell secretome capacity to improve regenerative activity of keratinocytes and fibroblasts in vitro” which has been published in the flagship journal, Wound Repair and Regeneration, of the Wound Healing Society. [Read more…]

AGS Therapeutics Unveils Ambitious R&D Pipeline, Showcasing the Potential of its Universal Delivery System for Novel Therapeutics

April 7, 2023 By Cade Hildreth, Founder & President Leave a Comment

The company’s MEV universal delivery system has the potential to overcome biological barriers in the body and solve current drug delivery challenges.

Paris, April 3, 2023 – AGS Therapeutics, an early-stage biotech company pioneering micro-algae extracellular vesicles (MEV) as a new delivery system for innovative therapeutic treatments, today announced its initial internal research and development (R&D) pipeline. It is designed to showcase the potential of its MEVs as a new groundbreaking delivery system for bringing a wide range of payloads, including mRNA, siRNA, plasmid-DNA, antisense oligonucleotides (ASO), peptides, and proteins, to a variety of tissues and organs for treatment of a wide range of diseases. MEVs can overcome many of the challenges met by current delivery systems based on mammalian extracellular vesicles and on synthetic lipid nanoparticles. [Read more…]

U.S. FDA Grants RMAT Designation to Intellia Therapeutics for NTLA-2002 in Treatment of Hereditary Angioedema

March 28, 2023 By Cade Hildreth, Founder & President Leave a Comment

March 21, 2023, CAMBRIDGE, Mass. – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE. [Read more…]

Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling

March 24, 2023 By Cade Hildreth, Founder & President Leave a Comment

SAN FRANCISCO–Tempo Bioscience, Inc. (“Tempo”), a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: [Read more…]

GOOD Meat, the World’s First-to-Market Cultivated Meat Company, Receives U.S. FDA Clearance

March 23, 2023 By Cade Hildreth, Founder & President Leave a Comment

Acclaimed chef José Andrés will be first in the country to serve GOOD Meat’s chicken

ALAMEDA, Calif.–GOOD Meat, the cultivated meat division of food technology company Eat Just, Inc., announced today that it has received a “no questions” letter from the U.S. Food and Drug Administration as part of one of the agency’s first pre-market consultations for a new kind of meat, poultry and seafood made from cells instead of raised and slaughtered animals. The letter means that following a careful and rigorous evaluation, the FDA has accepted the company’s conclusion that its first poultry product, cultivated chicken, is safe to eat. [Read more…]